The nation of Zimbabwe has turned down a significant US healthcare agreement worth 367 million US dollars (£272m) over five years because of Washington's request for confidential information.
The decision came to light after a official document dated December was leaked, indicating that President Emmerson Mnangagwa believed the agreement was "lopsided".
A government representative has since explained that the US was requesting health data for research and commercial purposes but was unwilling to share the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had furnished over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for further talks to secure a agreement acceptable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Implications
This rejection follows a comparable case in neighbouring Kenya, where a court halted a related health funding agreement after concerns were raised about the safety of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and accountability.
As per statements, Sixteen African countries have to date signed these new agreements, representing over $18.3bn in committed funds.
Details of the Rejected Agreement
The funds for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"Effectively, our nation would supply the basic resources for scientific discovery with no certainty that the final treatments would be available to our population should a future disease outbreak arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting systems already established through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to manage potential pandemics.
"This mechanism is intended to ensure that when a country provides its data, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," he added.
"We are open to further dialogue with our US partners on how subsequent co-operation could be structured in a way that respects the independence and interests of both nations."
Medical Community Reaction
Medical experts said it acknowledged the official position, but urged that talks must proceed given that much of the nation's HIV programmes depended on external financing.
"In cases where technical issues exist, including those relating to information security or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," it said.
The situation emphasises the ongoing debate between receiving vital international aid and safeguarding national sovereignty in an ever more data-driven world.